Epidemiologist, “Coalition Builder” Mayne To Lead CFSAN
This article was originally published in The Tan Sheet
Executive Summary
Susan Mayne will succeed Michael Landa at the CFSAN helm in January 2015. Supplement industry stakeholders are encouraged FDA filled the post ahead of Landa’s retirement after feeling the impact of vacancies in CFSAN offices regulating the industry.
You may also be interested in...
In Brief: Abbott Outlook; CFSAN’s Landa To Retire; FTC Claim Substantiation
Abbott “on track” in China recovery; CFSAN seeks new director; FTC adds new substantiation elements to settlement; NAD advises iSatori to amend claims energy supplement claims; FDA wants proof deficiencies are corrected; and FDA warns about chelation supplement.
FDA Revision Of NDI Draft Guidance Starts With Grandfathered List
Trade groups say FDA committed to revisiting issues in the NDI draft guidance including how firms prove ingredients’ grandfathered status, notifications required for ingredients or finished products and data necessary to demonstrate NDI safety. The agency’s decision followed a meeting between industry allies Sens. Hatch and Harkin and FDA Commissioner Hamburg.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”